SELLAS Life Sciences Group, Inc. (SLS) is a Healthcare stock trading at $11.54 (as of 2026-09-11), with a market capitalization of $2.15B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
SELLAS Life Sciences Group, Inc. is a biopharmaceutical company developing cancer immunotherapies, including galinpepimut-S (GPS) targeting Wilms tumor 1 and nelipepimut-S targeting HER2. Its programs are evaluated in clinical trials in areas such as acute myeloid leukemia, ovarian cancer, and early-stage breast cancer, including a collaboration with Merck to assess GPS with pembrolizumab across multiple indications.
SELLAS develops cancer immunotherapies, including GPS and nelipepimut-S, and would make money by commercializing successful treatments after approval.
SELLAS's profit model hinges on clinical success, because it must advance cancer immunotherapies toward approval and commercialization before building a product business.
Business quality (Unprofitable): SELLAS is unprofitable, with a reported gross margin of 90% and operating margin of -4195%.
| Price | $11.54 |
| Market Cap | $2.15B |
| Price / Book | 15.60 |
| Revenue (TTM) | $0.00 |
| Return on Equity | -24.4% |
| Current Ratio | 18.83 |
| Revenue Growth (YoY) | -100.0% |
| Revenue Growth (3Y) | -100.0% |
| EPS Growth (YoY) | -37.1% |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Insider Buys (12mo) | 1 |
| Top Institutional Holder | BlackRock, Inc. ($222.44M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Angelos Stergiou |
| Employees | 15 |
| Country | US |
| IPO Date | 2008-03-12 |
Data as of 2026-09-11.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.